Founded out of Yale University, CGI (formerly Cellular Genomics Inc.) began operations in 2000. CGI, in conjunction with several biotech and pharmaceutical partners (Pfizer, Serono, Lilly, Affymetrix, and Schering AG), utilized a unique chemical-genetics approach known as “ASKA” (Analog Sensitive Kinase Alleles) to understand kinase function. CGI Pharmaceuticals is dedicated to the discovery and development of breakthrough small molecule therapeutics for a broad range of oncology and allergy/autoimmune/inflammatory disease (AAID) indications. The Company’s fully integrated drug discovery infrastructure comprises proprietary kinase biology and chemistry, extensive lead generation and optimization capabilities, as well as drug metabolism/pharmacokinetics (DMPK) expertise. Utilizing its comprehensive chemistry capabilities, CGI has generated a proprietary small molecule kinase inhibitor library of over 50,000 compounds (all compounds designed and synthesized by CGI). To date, CGI has been awarded 8 U.S. patents covering its novel collection of kinase inhibitors. Moreover, all three of CGI’s drug discovery and development programs are based on hits obtained from CGI’s library.

Neurobiological Technologies, Inc. engages in the manufacture of biological products. The company was founded by Enoch Callaway and John B. Stuppin on August 27, 1987 and is headquartered in Emeryville, CA.

Nantong Repuel Bioengineering Co., Ltd., established on 2001-10-18, Business scope includes licensed projects:Import and export;food business;Tobacco retail(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Biochemical product technology research and development;Chemical product sales(No licensed chemical products);General Cargo Warehousing Services(Does not contain hazardous chemicals and other items that require approval);Non-residential real estate leases;General merchandise sales;Mechanical Parts,Parts sales;property management;Household Goods Sales;Arts and crafts and collectibles retail(Except for ivory and its products);Arts and crafts and collectibles wholesale(Except for ivory and its products);Wholesale of kitchenware, sanitary ware and daily sundries;Wholesale of hardware products;Hardware retail;furniture sales(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Part of Danone SA, Nutricia NV is a Dutch company located in Zoetermeer that manufactures dry, condensed and evaporated dairy products.

Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing genome engineering capabilities to develop targeted therapeutics for patients with high unmet medical needs. The company develops a pipeline of autologous and allogeneic chimeric antigen receptor T cell or CAR-T, product candidates focusing on the treatment of hematological malignancies and solid tumors. Poseida Therapeutics was founded in 2014 and is headquartered in San Diego, California.

Vindico NanoBioTechnology LLC develops novel and life-saving therapies. The company is headquartered in San Diego, CA.

Shenzhen Yuanjian Life Technology Co., Ltd., established on 2015-08-12, Business scope includes general business items:traditional Chinese medicine,chemical medicine,Technology development of biopharmaceuticals;Health food science and technology research and product technology development;Medical device technology research and product technology development.,The licensing program is:medicine,Production of health food and medical devices,Sales.

Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.

Beijing Zhongyan Tongrentang Pharmaceutical Research and Development Co., Ltd., established on 2003-10-23, The business scope includes traditional Chinese medicine products,Equipment technical development,Technical Services;Technical testing.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Accencio is an intellectual property strategy and intelligence company. It provides visualized intellectual property strategy and intelligence for molecular-based industry and research. It offers unique, interactive visualizations and analysis to the customers.

Tongrentang is a long-established brand of Chinese medicine industry. It has been established since 1669 and has a history of more than 300 years. In August 1992, China Tongrentang Group Corporation was formally established. In June 1997, Beijing Tongrentang Co., Ltd. was listed on the Shanghai Stock Exchange. In March 2000, Beijing Tongrentang Co., Ltd. sank part of the excellent assets to form Beijing Tongrentang Technology Development Co., Ltd., and listed on the Growth Enterprise Market of the Hong Kong Stock Exchange at the end of October of the same year. After the listing, Tong Ren Tang Technology has maintained a good performance and was officially transferred to the main board of the Hong Kong Stock Exchange on July 9, 2010, stock code 01666. Tongrentang Technology, as a high-tech modern Chinese medicine enterprise under the Tongrentang Group, integrates production, supply and marketing, insists on inheriting and carrying forward the Tongrentang royal medicine pharmaceutical tradition, relying on modern pharmaceutical technology, and taking “same repairing Rende, helping the world to maintain health” as its responsibility, insisting on “recipe Unique, superior materials, exquisite craftsmanship, and remarkable curative effect. All production workshops are designed, modified and operated in strict accordance with GMP standards. They are famous for their high production potential, large dosage forms and good product quality. They company not only has all production lines. All of them have passed the national GMP certification, and also have a number of production lines that have passed the Australian TGA certification and the Japanese Ministry of Health and Welfare certification. The company also passed the IS09001 quality system certification as early as 2003.

Yeastern Biotech Co., Ltd. is a Taiwanese private company located in Taipei that manufactures molecular biological reagents, health foods and cosmeceutical products.

Aiwo Biotechnology (Suzhou) Co., Ltd., established on 2014-08-28, Business scope includes technology development in the field of biotechnology,technical consulting,technology transfer,Technical Services;Research and development of blood separation and purification technology,Research and development and sales of blood separation equipment;Medical Equipment Leasing,repair;one type,Class II medical device,Daily necessities,Sales and after-sales service of office supplies;Medical polymer materials and filters for blood purification equipment,pipeline development,Sales;Development of software for medical devices,Sales;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Suzhou Proda Biotechnology Co., Ltd., established on 2012-12-22, Business scope includes biomedicine,Health products,food,cosmetic,medical instruments,Non-hazardous chemical products,Research and development of sewage treatment technology,Technical cooperation,technical consulting,technology transfer;Sales:Non-hazardous chemical products,Class I medical device,cosmetic.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

L & C Bio Co., Ltd. is making the health and happiness of mankind based on their mission to improve the quality of human life and to give better value to their customers. And the efforts of L & C Bio Co., Ltd. start with the business philosophy of 'respecting customers', 'grasping needs' and 'providing the best products and services

Yield10 Bioscience, Inc. is an agricultural bioscience company, which engages in the development of oilseed Camelina sativa as a platform crop for large scale production of low carbon sustainable seed products. The company was founded by Anthony J. Sinskey, Simon F. Williams, and Oliver P. Peoples in 1992 and is headquartered in Woburn, MA.

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of the hepatorenal syndrome.